Mirador Therapeutics, a closely guarded immune disease startup that has raised more than $650 million in venture funding, is beginning to show what it has been working on.
According to Endpoints News, the San Diego biotech said Thursday it had reached a deal for worldwide rights to a drug from a company called Kira. Endpoints reports that the candidate is positioned to rival Tavneos, an existing treatment.
The disclosure is notable because Mirador has said little publicly despite its unusually large war chest. Revealing even a single asset gives outside observers a first concrete look at how the company plans to compete in the immune and inflammatory disease space.
Beyond the fact that the drug comes from Kira, carries global rights, and is being framed as a Tavneos competitor, the company has not detailed the rest of its pipeline. Endpoints describes this as only "a piece" of what Mirador is building.
Why it matters: A biotech sitting on more than $650 million in funding rarely stays quiet, so Mirador's decision to name a licensed drug and a target rival signals it is moving from stealth toward an actual market fight — and gives patients, investors, and competitors their first real gauge of where its money is going.